In vitro and in vivo evaluation of kojic acid against Toxoplasma gondii in experimental models of acute toxoplasmosis
Copyright © 2019. Published by Elsevier Inc..
As current toxoplasmosis chemotherapies have many side effects along with toxicity on patients, we examined the anti-Toxoplasma effect of a biologically important natural antibiotic, kojic acid, in vitro and in vivo. Vero cells were incubated with different concentrations of kojic acid or pyrimethamine (positive control), and the cellular viability was determined. Next, Vero cells were infected with T. gondii (RH strain) and treated with drugs. Then, we calculated the infection index, T. gondii intracellular proliferation and the number and measure of plaque. Moreover, the effect of kojic acid on survival times, serum levels of IFN-γ and TNF-α and histopathological changes in the liver and spleen of Balb/c mice infected with T. gondii were determined. Kojic acid reduced the infection index, intracellular proliferation, the number and measure of plaque in vitro when compared to untreated infected cells. Kojic acid (100 mg/kg/day) also showed a better survival rate than infected untreated control mice (P < 0.05). IFN-γ and TNF-α secretions were significantly increased by kojic acid treatment in comparison to untreated groups (P < 0.05). In addition, its inhibitory effects on inflammatory alterations, apoptosis, and necrosis have been shown in sections of liver and spleen. We conclude that kojic acid exhibit potent anti-Toxoplasma activity with direct and indirect effects on the parasite, although further studies are needed before consideration of clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:200 |
|---|---|
| Enthalten in: |
Experimental parasitology - 200(2019) vom: 15. Mai, Seite 7-12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Montazeri, Mahbobeh [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.05.2019 Date Revised 10.12.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.exppara.2019.03.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM295271973 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM295271973 | ||
| 003 | DE-627 | ||
| 005 | 20231225083311.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.exppara.2019.03.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0984.xml |
| 035 | |a (DE-627)NLM295271973 | ||
| 035 | |a (NLM)30904693 | ||
| 035 | |a (PII)S0014-4894(18)30414-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Montazeri, Mahbobeh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vitro and in vivo evaluation of kojic acid against Toxoplasma gondii in experimental models of acute toxoplasmosis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.05.2019 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019. Published by Elsevier Inc. | ||
| 520 | |a As current toxoplasmosis chemotherapies have many side effects along with toxicity on patients, we examined the anti-Toxoplasma effect of a biologically important natural antibiotic, kojic acid, in vitro and in vivo. Vero cells were incubated with different concentrations of kojic acid or pyrimethamine (positive control), and the cellular viability was determined. Next, Vero cells were infected with T. gondii (RH strain) and treated with drugs. Then, we calculated the infection index, T. gondii intracellular proliferation and the number and measure of plaque. Moreover, the effect of kojic acid on survival times, serum levels of IFN-γ and TNF-α and histopathological changes in the liver and spleen of Balb/c mice infected with T. gondii were determined. Kojic acid reduced the infection index, intracellular proliferation, the number and measure of plaque in vitro when compared to untreated infected cells. Kojic acid (100 mg/kg/day) also showed a better survival rate than infected untreated control mice (P < 0.05). IFN-γ and TNF-α secretions were significantly increased by kojic acid treatment in comparison to untreated groups (P < 0.05). In addition, its inhibitory effects on inflammatory alterations, apoptosis, and necrosis have been shown in sections of liver and spleen. We conclude that kojic acid exhibit potent anti-Toxoplasma activity with direct and indirect effects on the parasite, although further studies are needed before consideration of clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute toxoplasmosis | |
| 650 | 4 | |a In vitro | |
| 650 | 4 | |a In vivo | |
| 650 | 4 | |a Kojic acid | |
| 650 | 4 | |a Toxoplasma gondii | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Antiprotozoal Agents |2 NLM | |
| 650 | 7 | |a Pyrones |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a kojic acid |2 NLM | |
| 650 | 7 | |a 6K23F1TT52 |2 NLM | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 650 | 7 | |a Pyrimethamine |2 NLM | |
| 650 | 7 | |a Z3614QOX8W |2 NLM | |
| 700 | 1 | |a Emami, Saeed |e verfasserin |4 aut | |
| 700 | 1 | |a Asgarian-Omran, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Azizi, Soheil |e verfasserin |4 aut | |
| 700 | 1 | |a Sharif, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Sarvi, Shahabeddin |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghi, Mitra |e verfasserin |4 aut | |
| 700 | 1 | |a Gohardehi, Shaban |e verfasserin |4 aut | |
| 700 | 1 | |a Daryani, Ahmad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Experimental parasitology |d 1953 |g 200(2019) vom: 15. Mai, Seite 7-12 |w (DE-627)NLM000040436 |x 1090-2449 |7 nnns |
| 773 | 1 | 8 | |g volume:200 |g year:2019 |g day:15 |g month:05 |g pages:7-12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.exppara.2019.03.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 200 |j 2019 |b 15 |c 05 |h 7-12 | ||